Products
Iluzanebart Biosimilar Monoclonal Antibody (TREM2) for Research
Cat No.: GMP-Bios-INN-1230
Anti-TREM2 therapeutic antibody (Pre-made Iluzanebart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Iluzanebart (development code VGL101) is a monoclonal antibody targeting TREM2 (triggering receptor expressed on myeloid cells 2). It is developed by Amgen for leukoencephalopathies and neurodegenerative disorders. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1230-1mg | 1mg | 3090 |
| GMP-Bios-INN-1230-10mg | 10mg | |
| GMP-Bios-INN-1230-100mg | 100mg | |
| GMP-Bios-INN-1230-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Iluzanebart biosimilar, Whole mAb, Anti-TREM2 Antibody: Anti-TREM2/Triggering receptor expressed on myeloid cells 2/TREM-2/Triggering receptor expressed on monocytes 2 therapeutic antibody |
| INN Name | Iluzanebart |
| Target | TREM2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Amgen |
| Conditions Approved | na |
| Conditions Active | Leukoencephalopathies;Neurodegenerative disorders |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
